Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study.
Hernandez-Fuentes MP, Franklin C, Rebollo-Mesa I, Mollon J, Delaney F, Perucha E, Stapleton C, Borrows R, Byrne C, Cavalleri G, Clarke B, Clatworthy M, Feehally J, Fuggle S, Gagliano SA, Griffin S, Hammad A, Higgins R, Jardine A, Keogan M, Leach T, MacPhee I, Mark PB, Marsh J, Maxwell P, McKane W, McLean A, Newstead C, Augustine T, Phelan P, Powis S, Rowe P, Sheerin N, Solomon E, Stephens H, Thuraisingham R, Trembath R, Topham P, Vaughan R, Sacks SH, Conlon P, Opelz G, Soranzo N, Weale ME, Lord GM; United Kingdom and Ireland Renal Transplant Consortium (UKIRTC) and the Wellcome Trust Case Control Consortium (WTCCC)-3. Hernandez-Fuentes MP, et al. Among authors: clarke b. Am J Transplant. 2018 Jun;18(6):1370-1379. doi: 10.1111/ajt.14594. Epub 2018 Feb 1. Am J Transplant. 2018. PMID: 29392897 Free PMC article.
C3d-positive donor-specific antibodies have a role in pretransplant risk stratification of cross-match-positive HLA-incompatible renal transplantation: United Kingdom multicentre study.
Babu A, Khovanova N, Shaw O, Griffin S, Briggs D, Krishnan NS, Fletcher S, Imray C, Seitz A, Baker R, Wellberry-Smith M, Clarke B, Cullen K, Rees T, Edwards F, Burrows E, Howe L, Martin C, Dorling A, Zehnder D, Higgins RM, Mitchell DA, Daga S. Babu A, et al. Among authors: clarke b. Transpl Int. 2020 Sep;33(9):1128-1139. doi: 10.1111/tri.13663. Epub 2020 Jun 25. Transpl Int. 2020. PMID: 32479670 Free article.
Clinical Significance of Alloantibodies in Hand Transplantation: A Multicenter Study.
Berglund E, Andersen Ljungdahl M, Bogdanović D, Berglund D, Wadström J, Kowalski J, Brandacher G, Kamińska D, Kaufman CL, Talbot SG, Azari K, Landin L, Höhnke C, Dwyer KM, Cavadas PC, Thione A, Clarke B, Kay S, Wilks D, Iyer S, Iglesias M, Özkan Ö, Özkan Ö, Krapf J, Weissenbacher A, Petruzzo P, Schneeberger S. Berglund E, et al. Among authors: clarke b. Transplantation. 2019 Oct;103(10):2173-2182. doi: 10.1097/TP.0000000000002650. Transplantation. 2019. PMID: 30817406
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.
Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V, Horowitz MM, Madrigal JA, Morishima Y, Oudshoorn M, Ringden O, Spellman S, Velardi A, Zino E, Petersdorf EW; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Fleischhauer K, et al. Lancet Oncol. 2012 Apr;13(4):366-74. doi: 10.1016/S1470-2045(12)70004-9. Epub 2012 Feb 15. Lancet Oncol. 2012. PMID: 22340965 Free PMC article.
Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.
Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, Kato S, Cesbron A, Tiercy JM, Senitzer D, Velardi A, Petersdorf EW; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Morishima Y, et al. Biol Blood Marrow Transplant. 2013 Aug;19(8):1197-203. doi: 10.1016/j.bbmt.2013.05.020. Epub 2013 Jun 6. Biol Blood Marrow Transplant. 2013. PMID: 23747601 Free PMC article.
Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
Goeldlin MB, Hakim A, Branca M, Abend S, Kneihsl M, Valenzuela Pinilla W, Fenzl S, Rezny-Kasprzak B, Rohner R, Strbian D, Paciaroni M, Thomalla G, Michel P, Nedeltchev K, Gattringer T, Sandset EC, Bonati L, Aguiar de Sousa D, Sylaja PN, Ntaios G, Koga M, Gdovinova Z, Lemmens R, Bornstein NM, Kelly P, Katan M, Horvath T, Dawson J, Fischer U; ELAN Investigators. Goeldlin MB, et al. JAMA Neurol. 2024 May 28:e241450. doi: 10.1001/jamaneurol.2024.1450. Online ahead of print. JAMA Neurol. 2024. PMID: 38805207
FGF21 acts in the brain to drive macronutrient-specific changes in behavioral motivation and brain reward signaling.
Khan MSH, Kim SQ, Ross RC, Corpodean F, Spann RA, Albarado DA, Fernandez-Kim SO, Clarke B, Berthoud HR, Münzberg H, McDougal DH, He Y, Yu S, Albaugh VL, Soto P, Morrison CD. Khan MSH, et al. Among authors: clarke b. bioRxiv [Preprint]. 2024 May 13:2024.03.05.583399. doi: 10.1101/2024.03.05.583399. bioRxiv. 2024. PMID: 38798313 Free PMC article. Preprint.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Among authors: clarke b. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.
Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, Molina CA, Bereczki D, Toni D, Seiffge DJ, Tanne D, Sandset EC, Tsivgoulis G, Christensen H, Beyer-Westendorf J, Coutinho JM, Crowther M, Verhamme P, Amarenco P, Roine RO, Mikulik R, Lemmens R, Veltkamp R, Middeldorp S, Robinson TG, Milling TJ Jr, Tedim-Cruz V, Lang W, Himmelmann A, Ladenvall P, Knutsson M, Ekholm E, Law A, Taylor A, Karyakina T, Xu L, Tsiplova K, Poli S, Kallmünzer B, Gumbinger C, Shoamanesh A; ANNEXA-I Investigators. Connolly SJ, et al. N Engl J Med. 2024 May 16;390(19):1745-1755. doi: 10.1056/NEJMoa2313040. N Engl J Med. 2024. PMID: 38749032 Clinical Trial.
1,568 results